Upadacitinib After TNF Inhibitor Failure Improves RA Control
A recent study found that switching to upadacitinib after failing a TNF inhibitor significantly improved disease control in rheumatoid arthritis patients compared to cycling to adalimumab. At 12 weeks, a higher percentage of patients on upadacitinib achieved low disease activity with similar safety profiles between the two treatments. The study highlights the importance of personalized treatment decisions based on individual patient profiles and ongoing research for long-term efficacy and safety.
- ▪Switching to upadacitinib resulted in superior disease control compared to cycling to adalimumab.
- ▪At week 12, 43.3% of patients on upadacitinib achieved a Disease Activity Score in 28 joints using CRP ≤ 3.2, compared to 22.4% on adalimumab.
- ▪The study was conducted across 218 sites in 24 countries with 491 patients participating.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Switching to upadacitinib after failure of a first TNF inhibitor resulted in superior disease control compared with cycling to adalimumab in patients with rheumatoid arthritis (RA). At 12 weeks, more patients receiving upadacitinib achieved low disease activity, with comparable safety profiles between treatments.METHODOLOGY:Researchers conducted a randomized phase 3b/4 trial across 218 sites in 24 countries to determine whether switching to a JAK inhibitor or cycling to another TNF inhibitor would be more efficacious for patients with active RA who previously had an inadequate response or intolerance to a single non-adalimumab TNF inhibitor while receiving stable methotrexate.A total of 491 patients (mean age, 55.6 years; 77.4% female) were randomly assigned to receive either 15…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
